Oculis Holding AG (NASDAQ:OCS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $43.8571.

OCS has been the subject of a number of analyst reports. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright upped their target price on shares of Oculis from $42.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. assumed coverage on shares of Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target on the stock. Lifesci Capital began coverage on Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target for the company. Finally, Needham & Company LLC boosted their price objective on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently bought and sold shares of OCS. Syquant Capital Sas purchased a new stake in Oculis in the 4th quarter valued at $3,849,000. Aventura Private Wealth LLC purchased a new position in Oculis during the 4th quarter worth $80,000. Bosun Asset Management LLC purchased a new position in Oculis during the 2nd quarter worth $378,000. Alps Advisors Inc. bought a new stake in shares of Oculis in the 4th quarter worth $938,000. Finally, Marshall Wace LLP bought a new stake in shares of Oculis in the 4th quarter worth $914,000. Institutional investors own 22.30% of the company’s stock.

Oculis Price Performance

Shares of OCS opened at $24.99 on Friday. The business’s fifty day moving average is $27.44 and its 200 day moving average is $22.42. Oculis has a 12-month low of $14.00 and a 12-month high of $30.68. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.45 billion, a P/E ratio of -11.01 and a beta of 0.29.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. Sell-side analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.